Pfizer Inc.
Pfizer Reaffirms Fiscal Year 2026 Guidance
Summary
Pfizer Inc. has reaffirmed its fiscal year 2026 guidance, maintaining the previously announced revenue range of $59.5 to $62.5 billion and the Adjusted Diluted EPS range of $2.80 to $3.00. This reaffirmation follows the recent announcement of the transition of the Chief Financial Officer. Further details can be found in Pfizer's 2026 First Quarter Earnings Release issued on May 5, 2026.
Profitelligence Alerts
Get alerts for PFE
Be first to know when Pfizer Inc. files with the SEC.
Filing Categories
Advertisement
About Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation, recognized for its role in the research, development, and manufacturing of healthcare products. Operating in the health sector, Pfizer focuses on creating innovative medicines and vaccines that significantly improve patients' lives. It is renowned for its contributions to pivotal health areas, such as oncology, immunology, cardiovascular health, and rare diseases. Pfizer maintains a robust pipeline of products at various stages of clinical development, enhancing its market position and impact. The company is instrumental in the global pharmaceutical landscape, contributing to public health with breakthroughs like vaccines and therapies that tackle some of the world's most challenging diseases. Headquartered in New York City, Pfizer plays a critical role in addressing urgent medical needs worldwide and is involved in extensive collaborations with scientific communities and healthcare systems. As a key player in the pharmaceutical industry, Pfizer’s developments and strategic initiatives can influence market trends and health policies, underscoring its importance in the global effort to combat health issues.
Official SEC Documents
Advertisement